Details for New Drug Application (NDA): 016807
✉ Email this page to a colleague
NDA 016807 describes THYROLAR-5, which is a drug marketed by Allergan and is included in one NDA. Additional details are available on the THYROLAR-5 profile page.
The generic ingredient in THYROLAR-5 is liotrix (t4;t3). Additional details are available on the liotrix (t4;t3) profile page.
The generic ingredient in THYROLAR-5 is liotrix (t4;t3). Additional details are available on the liotrix (t4;t3) profile page.
Summary for 016807
| Tradename: | THYROLAR-5 |
| Applicant: | Allergan |
| Ingredient: | liotrix (t4;t3) |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 0.0125MG;0.0031MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 0.1MG;0.025MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 0.15MG;0.0375MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
